Loading clinical trials...
Loading clinical trials...
To evaluate the clinical and echocardiographic outcome of LCZ696 therapy in HFrEF (NYHA Class II - IV and EF =≤ 40%).patients, in addition to the efficacy of LCZ696 in reducing mortality and rehospita...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mohammed Alnims
NCT07595809 · Heart Failure With Reduced Ejection Fraction
NCT07352891 · Heart Failure With Reduced Ejection Fraction
NCT06148935 · Chronic Heart Failure With Reduced Ejection Fraction
NCT07465653 · Heart Failure With Reduced Ejection Fraction
NCT07057466 · Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis), and more
Cairo University
Cairo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions